VANCOUVER, May 29, 2018 /CNW/ - InMed Pharmaceuticals
Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully
integrated, cannabinoid-based biopharmaceutical company that
leverages its proprietary biosynthesis platform technology to
develop novel therapeutics for the treatment of diseases with high
unmet medical needs, today announced that Eric A. Adams, President and Chief Executive
Officer of InMed, will be presenting at the 8th annual
LD Micro Invitational conference on June
4th, 2018, at 2:00 PM
PST at the Luxe Sunset Bel Air in Los Angeles, California.
A live webcast of the presentation will be available on InMed's
website. A replay will be available after the presentation
ends.
About InMed:
InMed is a pre-clinical stage
biopharmaceutical company that specializes in developing novel
therapies through the research and development into the extensive
pharmacology of cannabinoids coupled with innovative drug delivery
systems. InMed's proprietary bioinformatics database drug/disease
targeting tool, cannabinoid biosynthesis technology and drug
development pipeline are the fundamental value drivers of the
Company. For more information, visit www.inmedpharma.com.
About INM-750. INM-750 is a proprietary, topical
cannabinoid product candidate targeted as a therapy in
epidermolysis bullosa (EB) and other potential dermatological and
wound-healing applications. It has been specifically designed with
the intent to: (i) modify the underlying cause of the disease in
certain patients with EB Simplex (EBS, the most common form of EB),
and (ii) to treat the major symptoms of the disease in all patients
with EB. Preclinical data generated previously demonstrates that
INM-750 may have a significant impact on certain symptoms of EB
(which may include improvement of wound area to promote healing,
reduction in pain, itch and inflammation, and providing
antimicrobial activity). These disease hallmarks are key
therapeutic targets for the effective treatment of EB as well as
several other dermatological conditions. Additionally, our data
indicate that INM-750 may have an impact on the underlying disease
by increasing the production of certain proteins, called keratins,
in the skin.
About Epidermolysis Bullosa (EB). EB is a group of
rare diseases that cause fragile, blistering skin. The
blisters may appear in response to minor injury, even from heat,
rubbing, scratching or adhesive tape. In severe cases, the
blisters may occur inside the body, such as the lining of the mouth
or the stomach. Most types of epidermolysis bullosa are
inherited. The condition usually presents in infancy or early
childhood. Epidermolysis bullosa has no cure.
About INM-085. InMed is developing a
stimulus-responsive, nanoparticle-laden vehicle for controlled
delivery of ophthalmic drugs into the aqueous humor of the eye. The
first application of this delivery vehicle will be for INM-085 as a
cannabinoid-based topical therapy targeting reduction of the
intraocular pressure associated with glaucoma as well as being
designed to serve as a neuro-protectant to the retinal ganglion
cells. INM-085 is intended for application as a once-per-day eye
drop administered immediately prior to the patient's bedtime,
intending to assist in reducing non-adherence with current glaucoma
therapies. Additionally, this novel, proprietary delivery system
for ocular drugs may also play an important role in enabling other
companies' proprietary ocular drug candidates or re-invigorating
the commercial potential of off-patent products that would benefit
from a once-a-day dosing regimen.
About Glaucoma. Glaucoma is a group of eye
conditions that damage the optic nerve, which is vital to good
vision. This damage is often caused by an abnormally high pressure
in your eye. It is the second leading cause of blindness
worldwide. It can occur at any age but is more common in older
adults. The most common form of glaucoma has no warning signs.
The effect is so gradual that you may not notice a change in vision
until the condition is at an advanced stage. Vision loss due
to glaucoma can't be recovered.
Cautionary Note Regarding Forward-Looking
Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively,
"forward-looking information") within the meaning of applicable
securities laws. Forward-looking information is based on
management's current expectations and beliefs and is subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Forward-looking information in this news release
includes statements about: presenting at the LD Micro Invitational
conference; INM-750's potential impact on EB; developing a
stimulus-responsive, nanoparticle-laden vehicle for controlled
delivery of ophthalmic drugs into the aqueous humor of the eye; the
potential of INM-085 to treat glaucoma; the potential applications
of our proprietary delivery system for other ocular drugs; and the
expected fundamental value drivers of the Company.
With respect to the forward-looking information contained in
this news release, InMed has made numerous assumptions regarding,
among other things: continued and timely positive preclinical and
clinical efficacy data; the speed of regulatory approvals; demand
for InMed's products; and continued economic and market
stability. While InMed considers these assumptions to be
reasonable, these assumptions are inherently subject to significant
business, economic, competitive, market and social uncertainties
and contingencies.
Additionally, there are known and unknown risk factors which
could cause InMed's actual results, performance or achievements to
be materially different from any future results, performance or
achievements expressed or implied by the forward-looking
information contained herein. Known risk factors include,
among others: preclinical and clinical testing may not produce the
desired results on a timely basis, or at all; regulatory
applications may not be approved on a timely basis, or at all;
economic or market conditions may worsen; and InMed's proprietary
bioinformatics database drug/disease targeting tool, cannabinoid
biosynthesis technology and drug development pipeline may not
deliver the expected level of results nor become the fundamental
value drivers of the Company. A more complete discussion of
the risks and uncertainties facing InMed is disclosed in InMed's
most recent Annual Information Form and other continuous disclosure
filed with Canadian securities regulatory authorities on SEDAR at
www.sedar.com.
All forward-looking information herein is qualified in its
entirety by this cautionary statement, and InMed disclaims any
obligation to revise or update any such forward-looking information
or to publicly announce the result of any revisions to any of the
forward-looking information contained herein to reflect future
results, events or developments, except as required by law.
NEITHER THE TORONTO
STOCK EXCHANGE NOR ITS REGULATIONS
SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE
ADEQUACY OR ACCURACY OF THIS RELEASE.
View original content with
multimedia:http://www.prnewswire.com/news-releases/inmed-to-present-at-the-8th-annual-ld-micro-invitational-conference-300654306.html
SOURCE InMed Pharmaceuticals Inc.